

DESCRIPTION

Species Reactivity	Mouse
Specificity	Detects mouse FCRLB/FCRY in direct ELISAs and Western blots. In Western blots, 75% cross-reactivity with recombinant human FCRLB is observed.
Source	Monoclonal Rat IgG _{2A} Clone # 465905
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant mouse FCRLB/FCRY Ala18-Ser427 Accession # Q5DRQ8
Conjugate	Alexa Fluor 488 Excitation Wavelength: 488 nm Emission Wavelength: 515-545 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

FCRLB, also known as FCRL2, FCY, and FREL2, is a 60 kDa protein with sequence homology to classical Fc receptors. There are at least six type 1 transmembrane FCRL proteins and two that lack transmembrane segments. Each family member contains between three and nine immunoglobulin-like domains. FCRL proteins are differentially expressed within the B cell lineage and can either promote or inhibit B cell proliferation and activation (1, 2). According to R&D Systems testing, FCRLB binds to purified mouse IgG. Mouse FCRLB shares 82% and 94% aa sequence identity with human and rat FCRLB, respectively. It contains a putative signal peptide, three immunoglobulin-like domains, and a mucin-like stalk that is rich in Pro, Ser, and Thr residues (1-3). The stalk region also contains di-Leu motifs and an unpaired cysteine (1-4). When expressed in transfectants, FCRLB is not secreted but shows a diffuse intracellular localization (4, 5). FCRLB is expressed at a low level in placenta and in B lineage cells of the germinal center (4, 5). It is upregulated in B cells by BAFF and LPS (3). Among non-hematopoietic cells, FCRLB is expressed in fibroblasts, melanocytes, and melanoma (3, 4, 6). It is preferentially expressed in nonproliferating cells and at the onset of apoptosis (3, 5).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.